Treatment of Primary Sjögren Syndrome With Rituximab: A Randomized Trial

医学 美罗华 临床终点 安慰剂 内科学 不利影响 随机化 痹症科 可视模拟标度 随机对照试验 胃肠病学 外科 淋巴瘤 病理 替代医学
作者
Valérie Devauchelle‐Pensec,Xavier Mariette,Sandrine Jousse‐Joulin,Jean‐Marie Berthelot,Aleth Perdriger,Xavier Puéchal,Véronique Le Guern,Jean Sibilia,Jacques‐Eric Gottenberg,Laurent Chiche,Eric HACHULLA,Pierre‐Yves Hatron,Vincent Goëb,Gilles Hayem,Jacques Morel,Charles Zarnitsky,Jean‐Jacques Dubost,Jacques‐Olivier Pers,Emmanuel Nowak,Alain Saraux
出处
期刊:Annals of Internal Medicine [American College of Physicians]
卷期号:160 (4): 233-242 被引量:492
标识
DOI:10.7326/m13-1085
摘要

BACKGROUND: Primary Sjögren syndrome (pSS) is an autoimmune disorder characterized by ocular and oral dryness or systemic manifestations. OBJECTIVE: To evaluate efficacy and harms of rituximab in adults with recent-onset or systemic pSS. DESIGN: Randomized, placebo-controlled, parallel-group trial conducted between March 2008 and January 2011. Study personnel (except pharmacists), investigators, and patients were blinded to treatment group. (ClinicalTrials.gov: NCT00740948). SETTING: 14 university hospitals in France. PATIENTS: 120 patients with scores of 50 mm or greater on at least 2 of 4 visual analogue scales (VASs) (global disease, pain, fatigue, and dryness) and recent-onset (< 10 years) biologically active or systemic pSS. INTERVENTION: Randomization (1:1 ratio) to rituximab (1 g at weeks 0 and 2) or placebo. MEASUREMENTS: Primary end point was improvement of at least 30 mm in 2 of 4 VASs by week 24. RESULTS: No significant difference between groups in the primary end point was found (difference, 1.0% [95% CI, -16.7% to 18.7%]). The proportion of patients with at least 30-mm decreases in at least two of the four VAS scores was higher in the rituximab group at week 6 (22.4% vs. 9.1%; P = 0.036). An improvement of at least 30 mm in VAS fatigue score was more common with rituximab at weeks 6 (P < 0.001) and 16 (P = 0.012), and improvement in fatigue from baseline to week 24 was greater with rituximab. Adverse events were similar between groups except for a higher rate of infusion reactions with rituximab. LIMITATION: Low disease activity at baseline and a primary outcome that may have been insensitive to detect clinically important changes. CONCLUSION: Rituximab did not alleviate symptoms or disease activity in patients with pSS at week 24, although it alleviated some symptoms at earlier time points.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1x1ao发布了新的文献求助10
刚刚
我是老大的应助被冬瓜鑫采纳,获得10
刚刚
chenisyu完成签到,获得积分10
1秒前
斯文败类的应助被朴实的以南采纳,获得10
1秒前
LYP完成签到,获得积分10
1秒前
1秒前
1秒前
上官若男的应助被xianggua采纳,获得10
2秒前
顺利毕业发布了新的文献求助10
2秒前
2秒前
2秒前
钟梓袄发布了新的文献求助10
3秒前
3秒前
3秒前
ke完成签到,获得积分10
3秒前
Lu完成签到 ,获得积分10
3秒前
4秒前
4秒前
ZJL完成签到,获得积分10
4秒前
倒拔垂杨柳的应助被多情的仰采纳,获得10
5秒前
在水一方的应助被端庄凝天采纳,获得10
5秒前
DW的应助被ppat5012采纳,获得10
5秒前
5秒前
Leo发布了新的文献求助10
5秒前
6秒前
高大的如彤完成签到 ,获得积分10
6秒前
化学胖子发布了新的文献求助100
6秒前
6秒前
孙航航完成签到,获得积分10
6秒前
英俊的铭的应助被真的头疼捏采纳,获得10
7秒前
lyx发布了新的文献求助10
7秒前
子书秋华完成签到,获得积分10
8秒前
41发布了新的文献求助10
8秒前
9秒前
绝版肉肉完成签到,获得积分10
9秒前
ciara完成签到,获得积分10
9秒前
柠A发布了新的文献求助10
9秒前
跳跃发布了新的文献求助10
9秒前
9秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124